UBS Group AG - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 179 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.

Quarter-by-quarter ownership
UBS Group AG ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$2,166,133
-30.3%
305,951
-30.7%
0.00%0.0%
Q2 2023$3,109,103
-13.8%
441,634
+2.1%
0.00%0.0%
Q1 2023$3,608,551
-51.4%
432,680
-33.0%
0.00%
-66.7%
Q4 2022$7,418,698
+185.3%
646,228
+213.2%
0.00%
+200.0%
Q3 2022$2,600,000
+61.3%
206,334
+35.4%
0.00%0.0%
Q2 2022$1,612,000
-30.8%
152,438
+6.5%
0.00%0.0%
Q1 2022$2,328,000
-68.4%
143,148
-73.1%
0.00%
-50.0%
Q4 2021$7,377,000
+51.7%
532,650
+57.4%
0.00%0.0%
Q3 2021$4,863,000
+71.8%
338,388
+89.0%
0.00%
+100.0%
Q2 2021$2,831,000
+47.0%
179,019
-5.5%
0.00%0.0%
Q1 2021$1,926,000
-51.0%
189,416
-64.1%
0.00%0.0%
Q4 2020$3,933,000
-20.3%
527,873
-63.3%
0.00%
-50.0%
Q3 2020$4,936,000
+552.0%
1,437,055
+804.5%
0.00%
Q2 2020$757,000
-92.6%
158,876
-96.9%
0.00%
-100.0%
Q1 2020$10,166,000
-46.3%
5,083,238
-7.4%
0.01%
-28.6%
Q4 2019$18,935,000
+117.6%
5,488,287
+80.7%
0.01%
+133.3%
Q3 2019$8,703,000
+4.2%
3,037,809
+37.9%
0.00%0.0%
Q2 2019$8,349,000
+100.7%
2,202,794
+331.0%
0.00%
+50.0%
Q1 2019$4,160,000
+310.7%
511,113
+307.1%
0.00%
Q4 2018$1,013,000
+18.6%
125,544
+12.2%
0.00%
Q3 2018$854,000
+135.9%
111,885
+76.9%
0.00%
Q2 2018$362,000
-74.0%
63,239
-78.3%
0.00%
-100.0%
Q1 2018$1,390,000
+181.9%
291,379
+190.7%
0.00%
Q4 2017$493,000
-17.6%
100,222
-12.2%
0.00%
Q3 2017$598,000
+69.4%
114,114
+79.8%
0.00%
Q2 2017$353,000
-41.7%
63,479
-11.9%
0.00%
Q1 2017$605,000
-4.3%
72,041
-27.8%
0.00%
Q4 2016$632,000
+62.5%
99,803
+13.1%
0.00%
Q3 2016$389,000
+62.8%
88,256
+4.9%
0.00%
Q2 2016$239,000
+16.0%
84,170
+15.6%
0.00%
Q1 2016$206,000
-86.3%
72,835
-50.0%
0.00%
-100.0%
Q4 2015$1,502,000
+72.1%
145,603
+90.2%
0.00%0.0%
Q3 2015$873,000
-20.9%
76,535
+3.6%
0.00%0.0%
Q2 2015$1,103,000
+64.9%
73,884
-0.3%
0.00%
Q1 2015$669,000
-27.1%
74,084
-1.8%
0.00%
-100.0%
Q4 2014$918,00075,4740.00%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Burrage Capital Management LLC 1,105,673$8,237,0006.28%
Sarissa Capital Management LP 8,175,000$60,903,0006.22%
ORACLE INVESTMENT MANAGEMENT INC 2,980,870$22,207,0002.78%
DG Capital Management, LLC 1,075,732$8,014,0001.70%
Ghost Tree Capital, LLC 900,000$6,705,0001.49%
Parkman Healthcare Partners LLC 538,370$4,011,0001.03%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 5,835,810$43,477,0000.86%
Formidable Asset Management, LLC 470,419$3,470,0000.80%
KNOTT DAVID M 219,461$1,635,0000.74%
Altium Capital Management LP 250,000$1,863,0000.70%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders